Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + pertussis + tetanus + Haemophilus influenzae type b vaccine
- Development stage
- Preclinical
- Lead developer
- Olymvax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Olymvax's Hexavaccine (DPT-AC-Hib) is a preclinical-stage hexavalent combination vaccine designed to provide simultaneous protection against six major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib), and meningococcal serogroups A and C. The vaccine formulation incorporates multiple antigens, including diphtheria and tetanus toxoids, acellular pertussis components, and conjugated polysaccharides for Hib and Neisseria meningitidis serogroups A and C. By consolidating these protections into a single administration, the vaccine aims to reduce the number of injections required for pediatric immunization, thereby improving compliance and coverage. It is currently in preclinical development by the Chinese biopharmaceutical company Olymvax.
- Other names
- DPT-AC-Hib Combination VaccineHexavalent DPT-AC-Hib vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)FIM2/3 (Fimbrial protein 2 and 3)Diphtheria toxinPRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on diphtheria + pertussis + tetanus + Haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + pertussis + tetanus + Haemophilus influenzae type b vaccine.